Summit Therapeutics (SMMT) Return on Equity (2019 - 2025)

Summit Therapeutics has reported Return on Equity for 7 years, with the latest figure at 0.0% in Q3 2025.

• For the quarter ending Q3 2025, Return on Equity changed 0.0% year-over-year to 0.0%; the trailing twelve-month figure through Sep 2025 stood at 0.0% (changed 0.0% YoY), and the FY2024 full-year result was 0.01%, up 5.0% from the prior year.
• Return on Equity for Q3 2025 stood at 0.0%, up from 0.0% in the prior quarter.
• The five-year high for Return on Equity was 0.0% in Q3 2025, with the low at 0.07% in Q4 2023.
• Historically, Return on Equity has averaged 0.02% across 5 years, with a median of 0.01% in 2021.
• Annual changes were most pronounced in 2023 — Return on Equity declined 6 bps — and 2024, when it rose 6 bps.
• Summit Therapeutics' Return on Equity stood at 0.01% in 2021, then surged by 42 bps to 0.01% in 2022, then plunged by 1141 bps to 0.07% in 2023, then surged by 92 bps to 0.01% in 2024, then jumped by 49 bps to 0.0% in 2025.
• The last three Return on Equity figures came in at 0.0% (Q3 2025), 0.0% (Q2 2025), and 0.01% (Q1 2025), per Business Quant data.